Poly Medicure
- Market cap
- ₹ 14,582 Cr.
- P/E
- 45.7x
- P/B
- 4.73x
- 52-week range
- 1,182 – 2,094.3
- ROE
- 9%
- ROCE
- 12%
- Dividend yield
- 0.2%
- Debt / equity
- 0.11
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Poly Medicure Limited is an India-based medical device manufacturer and exporter, with its products sold in over 125 countries. The Company is primarily in the business of manufacturing and selling medical devices. With a portfolio of over 200 medical devices and more than 330 patents, the Company offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anesthesia and respiratory care, urology, and surgery and wound management. Its products consist of an I.V. cannula, arterial cannula, prefilled syringe, nasogastric feeding tube, gastro-duodenal feeding tube, umbilical catheter, irrigation sets, urine drainage catheters and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Poly Medicure against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)45.7 against a typical 26.9: pricier than most peers (1st = cheapest).17th of 25
- Sales growth+30.3% against a typical +21.5% from a year earlier.7th of 18
- Profit growth−8.6% against a typical +13.4% from a year earlier.10th of 16
- Share price, 3 months−11.8% against a typical −7.9%.13th of 23
- Size₹ 14,581.6 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).1st of 24
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil AA- | Positive | 24 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 24 Jun 2026 | Rating action | Crisil AA- | — | CRISIL | ₹ 500 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 25 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 5 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 8 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 8 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 6 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the Audited financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 525 |
| Expenses | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 382 | 424 | 400 |
| Operating Profit | 84 | 90 | 96 | 104 | 115 | 114 | 119 | 106 | 115 | 111 | 110 | 125 |
| OPM % | 25% | 27% | 26% | 27% | 27% | 27% | 27% | 26% | 26% | 23% | 21% | 24% |
| Other Income | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 | 35 | 21 | 19 | 35 |
| Interest | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 | 6 |
| Depreciation | 16 | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 | 36 |
| Profit before tax | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 | 122 | 98 | 85 | 117 |
| Tax % | 23% | 26% | 26% | 25% | 26% | 25% | 25% | 24% | 25% | 27% | 24% | 27% |
| Net Profit | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 | 85 |
| EPS in Rs | 6.48 | 6.78 | 7.12 | 7.71 | 8.63 | 8.41 | 9.06 | 9.19 | 9.06 | 7 | 6.54 | 8.49 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 16%
- 5 Years
- 19%
- 3 Years
- 19%
- TTM
- 18%
- 10 Years
- 19%
- 5 Years
- 14%
- 3 Years
- 15%
- TTM
- −11%
- 10 Years
- 24%
- 5 Years
- 14%
- 3 Years
- 6%
- TTM
- —
- 10 Years
- 15%
- 5 Years
- 13%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Poly Medicure | ₹ 1,480.80 | ₹ 14,582 Cr. | 45.7x | 4.7x | 9% | — |
| Lenskart Solutions | ₹ 627.55 | ₹ 1,08,959 Cr. | 181x | 10.7x | 6.7% | 5.7% |
| Laxmi Dental | ₹ 171.25 | ₹ 946 Cr. | 35.6x | 5x | 12.8% | 9.5% |
| Mallcom (India) | ₹ 909.00 | ₹ 567 Cr. | 21.9x | 2.1x | 9.7% | 5.6% |
| One Global Service Provider | ₹ 372.00 | ₹ 721 Cr. | 17x | 8.3x | 65.2% | 14% |
| Hemant Surgical Industries | ₹ 570.00 | ₹ 829 Cr. | 26x | 3.7x | 18.1% | 7.9% |
Management
- Naresh Vijayvargiya
- Chief Financial Officer
- Avinash Chandra
- Compliance Officer, Company Secretary
- Himanshu Baid
- Managing Director, Executive Director
- Rishi Baid
- Joint Managing Director, Executive Director
- Vishal Baid
- Executive Director
- Pankaj Kumar Gupta
- Executive Director
- Ravi Prakash
- Deputy Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.